| Michel R Nasr, MD | |
|
200 Hawkins Dr, Iowa City, IA 52242-1009 | |
| (319) 356-2256 | |
| Not Available |
| Full Name | Michel R Nasr |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 25 Years |
| Location | 200 Hawkins Dr, Iowa City, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558560532 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZH0000X | Pathology - Hematology | 37129 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospital S U N Y Health Science Center | Syracuse, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Pathologists Laboratories, Llp | 8325038276 | 23 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Scientists have a developed a new technique to decipher how millions of individual cells are communicating with each other in miniature tumors grown in the lab, known as organoids, according to new research published in Nature Methods today (Monday).
Over recent months, a long list of consumer goods from China - everything from seafood to toothpaste to toys - have been the objects of recalls.
Highly active adults engage in a greater variety of physical activities than do less active adults, finds a new study led by researchers at NYU Rory Meyers College of Nursing.
› Verified 1 days ago
| Entity Name | University Pathologists Laboratories, Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033150917 PECOS PAC ID: 8325038276 Enrollment ID: O20040513001074 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Scientists have a developed a new technique to decipher how millions of individual cells are communicating with each other in miniature tumors grown in the lab, known as organoids, according to new research published in Nature Methods today (Monday).
Over recent months, a long list of consumer goods from China - everything from seafood to toothpaste to toys - have been the objects of recalls.
Highly active adults engage in a greater variety of physical activities than do less active adults, finds a new study led by researchers at NYU Rory Meyers College of Nursing.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michel R Nasr, MD 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 356-2256 | Michel R Nasr, MD 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 356-2256 |
News Archive
New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1
Scientists have a developed a new technique to decipher how millions of individual cells are communicating with each other in miniature tumors grown in the lab, known as organoids, according to new research published in Nature Methods today (Monday).
Over recent months, a long list of consumer goods from China - everything from seafood to toothpaste to toys - have been the objects of recalls.
Highly active adults engage in a greater variety of physical activities than do less active adults, finds a new study led by researchers at NYU Rory Meyers College of Nursing.
› Verified 1 days ago
Dr. John Phillip Lee, D.O. Pathology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Dept Of Pathology, Iowa City, IA 52242 Phone: 319-384-9605 Fax: 319-467-5193 | |
Dr. Carol Joy Holman, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-3981 Fax: 319-384-8051 | |
James A Goeken, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-1966 Fax: 319-384-8053 | |
Sergei I Syrbu, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-7372 Fax: 319-384-8053 | |
Jo A Benda, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-4436 Fax: 319-384-8052 | |
Amani Abdalla Bashir, MBBS Pathology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Drive, University Of Iowa Hospitals And Clinics, Iowa City, IA 52242 Phone: 319-467-5706 Fax: 319-356-8470 | |
Mr. Paul J Belding, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 321 E Market St Ste 102, Iowa City, IA 52245 Phone: 319-337-7284 Fax: 319-337-7284 |